Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor κB activation and subsequently suppressed ovarian cancer dissemination

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10464-10471

  Kobayashi, Hiroshi ^a   Yagyu, Tatsuo ^b   Kondo, Toshiharu ^c   Kurita, Noriyuki ^d   Inagaki, Kiyokazu ^b   Haruta, Shoji ^e   Kawaguchi, Ryuji ^e   Kitanaka, Takashi ^e   Sakamoto, Yoshiharu ^e   Yamada, Yoshihiko ^e   Kanayama, Naohiro ^a   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NetForce Co Ltd   (Japan)

^c Computer Technology Integration Co Ltd ^*  (Japan)

^d TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PACLITAXEL; THALIDOMIDE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BODY WEIGHT; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHONDROSARCOMA; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, CELL SURFACE; RNA, MESSENGER; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28544447468     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3789     Document Type: Article

References (48)

1. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
2. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A 1985;82:4939-43.
3. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
4. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 1992;667:13-31.
5. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998;13:893-906.
6. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE, de Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 1999;263:295-304.
7. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001;10:393-415.
8. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
9. Webb DJ, Nguyen DH, Gonias SL. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 2000;113:123-34.
10. Kruger A, Soeltl R, Lutz V, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9.
11. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994;337:131-4.
12. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13:3983-91.
13. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor β 1 in human A549 lung carcinoma cells. EMBO J 1991;10:3399-407.
14. Lund LR, Ellis V, Ronne E, Pyke C, Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995;310:345-52.
15. Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 1992;267:20493-6.
16. Mandriota SJ, Seghezzi G, Vassalli JD, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-16.
17. Kirchheimer JC, Nong YH, Remold HG. IFN-γ, tumor necrosis factor-α, and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 1988;141:4229-34.
18. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988;263:2358-63.
19. Wang H, Skibber J, Juarez J, Boyd D. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 1994;58:650-7.
20. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004;4:327-36.
21. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11.
22. Joglekar S, Levin M. The promise of thalidomide: evolving indications. Drugs Today (Bare) 2004;40:197-204.
23. Jin SH, Kim TI, Han DS, Shin SK, Kim WH. Thalidomide suppresses the interleukin 1β-induced NFκB signaling pathway in colon cancer cells. Ann N Y Acad Sci 2002;973:414-8.
24. Kikuchi Y, Kizawa I, Oomori K, et al. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 1987;47:592-6.
25. Takigawa M, Tajima K, Pan HO, et al. Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res 1989;49:3996-4002.
26. Tai Y-T, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling. Blood 2003; 101:2762-9.
27. Marschall C, Lengyel E, Nobutoh T, et al. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol 1999;113:69-76.
28. Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990;9:467-74.
29. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001;276:2015-22.
30. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
31. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
32. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998;273:8502-7.
33. Ried S, Jager C, Jeffers M, et al. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor. J Biol Chem 1999;274:16377-86.
34. Nguyen DH, Catling AD, Webb DJ, et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999;146:149-64.
35. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995;269:1270-2.
36. Reuning U, Wilhelm O, Nishiguchi T, et al. Inhibition of NF-κ B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but net its inhibitor PAI-1. Nucleic Acids Res 1995;23:3887-93.
37. Shetty S, Kumar A, Johnson A, Pueblitz S, Idell S. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am J Physiol 1995;268:L972-82.
38. Farese JP, Fox LE, Detrisac CJ, Van Gilder JM, Roberts SL, Baldwin JM. Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. Am J Vet Res 2004;65:659-64.
39. Fujii T, Tachibana M, Dhar DK, et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res 2003;23:2405-11.
40. Palencia G, Arrieta O, Rios C, Altagracia M, Kravzov J, Sotelo J. Effect of thalidomide in different tumors in rodents. J Exp Ther Oncol 2002;2:158-62.
41. Ding Q, Kestell P, Baguley BC, et al. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 2002;50:186-92.
42. Arrieta O, Guevara P, Tamariz J, Rembao D, Rivera E, Sotelo J. Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. Int J Exp Pathol 2002;83:99-104.
43. Douglas ML, Reid JL, Hii SI, Jonsson JR, Nicol DL. Renal cell carcinoma may adapt to and overcome antiangiogenic intervention with thalidomide. BJU Int 2002;89:591-5.
44. Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, Figg WD. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol 2003;46 Suppl:S49-57.
45. Gee MS, Makonnen S, al-Kofahi K, et al. Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition. Cancer Res 2003;63:8073-8.
46. Hattori Y, Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto) 2004;44:125-36.
47. Chen YT, Holcomb C, Moore HP. Expression and localization of two low molecular weight GTP-binding proteins, Rab8 and Rab10, by epitope tag. Proc Natl Acad Sci U S A 1993;90:6508-12.
48. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 2001;1547:26-36.